Skip to main content

Table 4 Multivariable logistic regression analysis to predict classification in pRLDA compared to pMDA group

From: Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group

pRLDA classification (vs pMDA) Univariable analysis Multivariable analysis
OR 95% CI p value OR 95% CI p value
Gender female (vs male) 0.31 0.18 to 0.52 p < 0.001* 0.38 0.17 to 0.84 p = 0.017*
Age (per year) 0.97 0.95 to 0.98 p < 0.001* 0.98 0.96 to 1.02 p = 0.26
Disease duration (per year) 1.01 0.98 to 1.03 p = 0.65 0.99 0.95 to 1.03 p = 0.68
Previous csDMARDs, count < 2 1.56 0.91 to 2.67 p = 0.11 1.11 0.49 to 2.5 p = 0.8
Anti-TNF baseline 5.54 1.3 to 23.57 p = 0.02* 2.9 0.51 to 16.55 p = 0.23
DAS28 baseline (per unit) 0.27 0.2 to 0.38 p < 0.001* 0.45 0.29 to 0.7 p < 0.001*
HAQ baseline (per unit) 0.21 0.11 to 0.4 p < 0.001* 0.53 0.2 to 1.38 p = 0.19
DAS28 1st semester (per unit) 0.17 0.11 to 0.25 p < 0.001* 0.19 0.12 to 0.29 p < 0.001*
ΔHAQ 1st semester < − 0.22 0.65 0.37 to 1.15 p = 0.14 0.38 0.16 to 0.91 p = 0.029*
  1. pRLDA persistent remission/low disease activity group, pMDA persistent moderate disease activity group, cDMARDs conventional synthetic disease-modifying antirheumatic drugs, 1st semester therapy months 3–9, HAQ Health Assessment Questionnaire, ΔHAQ HAQ difference 1st semester’s average from baseline, ACC accuracy, TPR sensitivity, TNR specificity, AUC area under receiver-operating-characteristic curve
  2. Multivariable analysis efficiency (10-fold cross-validation): ACC = 88.3%, TPR = 68%, TNR = 95%, AUC = 91%
  3. *Below significance threshold 0.05
\